Celltrion Healthcare continues to build on its achievements with Pharmacy Benefit Managers (PBMs) with the signing of Yuflyma (adalimumab) with Specialty Pharmacy, a key drug supply channel in the United States, the world's largest market for adalimumab.
Celltrion Healthcare announced on October 16 that Yuflyma has been added to the supply program managed by CarePartners Pharmacy, a leading U.S. specialty pharmacy chain, and will be available later this month through CarePartners Pharmacy's specialty pharmacies across the United States.
With this agreement, Yuflyma will cover more than 10 million patients enrolled in CarePartners Pharmacy and its affiliated channels.
Celltrion Healthcare added that the agreement to deliver Yuflyma directly to CarePartners Pharmacy will also have a positive impact on profitability by reducing distribution steps.
Celltrion Healthcare said the agreement is significant because it expands Yuflyma's distribution channels beyond PBMs to specialty pharmacy chains.
